With my oldest son, who is now 21, I never worried about limitations. He played soccer for a season, and that was the extent of his athletic pursuits. He just did not like sports and to this day, he does not understand the basics of a football game,…

In recognition of World Hemophilia Day 2018, the biopharmaceutical company Bioverativ is sharing the stories of people with hemophilia in the developing world to highlight the life-changing potential of adequate treatment. In honor of this year’s theme, “Sharing Knowledge Makes Us Stronger,” Bioverativ will collaborate with members of the hemophilia community…

The cost of hemophilia treatment doubled for patients who switched from standard half-life (SHL) to extended half-life (EHL) products, according to a recent study by Prime Therapeutics. The findings of the study were presented at the Academy of Managed Care Pharmacy’s (AMCP) Managed Care & Specialty…

Gene therapy delivered to muscle was able to completely correct hemophilia B deficient blood clotting in a safe and well-tolerated manner for several years — in animal models of the condition. The study with finding, “Complete correction of hemophilia B phenotype by FIX-Padua…

Magellan Rx Management, the pharmacy benefit management division of Magellan Health, recently shared results from the first six months of its hemophilia management program as it observed World Hemophilia Day April 17. The focus of the hemophilia management program is to reduce unnecessary costs while improving quality of care.

CSL Behring marked World Hemophilia Day April 17 by shipping more than 10 million international units (IUs) of its medicines to treat hemophilia A to developing countries through the nonprofit World Federation of Hemophilia (WFH). The medicines were sent to countries like Vietnam, Cameroon and others through the WFH’s…

The U.S. Food and Drug Administration granted breakthrough therapy designation to Genentech’s Hemlibra (emicizumab-kxwh) for people with hemophilia A without factor VIII inhibitors. Hemlibra is designed to bring together the proteins required to activate the natural coagulation cascade and restore the blood clotting process for patients with…

The Korean Ministry of Food and Drug Safety has agreed to Catalyst Biosciences’ request to add a sixth group to a Phase 1/2 clinical trial of its hemophilia B treatment. The sixth group in the trial (NCT03186677) of the therapy that Catalyst calls CB 2679d (ISU304) will include up…

Exercise can be an important part of recovering from hemophilia and continuing to keep a handle on it, according to a German review of previous research. The study, “Programmed Sports Therapy (PST) in People with Haemophilia (PwH) — Sports Therapy Model for Rare Diseases,”  appeared in the…

Researchers are creating a free web-based calculator that will help physicians determine the best patient-specific preventive regimens for children with hemophilia, according to a recent study. The tool is based on newly developed methods that identified key features of an effective preventive regimen. This includes giving Factor VIII (FVIII) injections…